Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

Table 4 The comparison of clinical data between the observation and control groups, n (%)

Clinical data	Observation group (n = 60)	Control group (n = 58)	t/χ2	P value
Age (yr)	54.49 ± 4.29	55.70 ± 5.10	-1.396	0.165
BMI (kg/m2)	22.02 ± 2.05	22.10 ± 2.54	-0.189	0.851
Karnofsky score (points)	74.40 ± 5.12	75.52 ± 6.02	-1.090	0.278
Differentiation degree			1.188	0.276
High differentiation	23 (38.33)	28 (48.28)
Medium low differentiation	37 (61.67)	30 (51.72)
Intravascular tumor thrombus			0.337	0.562
Yes	14 (23.33)	11 (18.97)
No	46 (78.33)	47 (81.03)
Tumor size			0.576	0.448
> 5 cm	29 (48.33)	24 (41.38)
≤ 5 cm	31 (51.67)	34 (58.62)
TNM stages			0.009	0.926
III	48 (80.00)	46 (79.31)
IV	12 (20.00)	12 (20.69)
Pathological type			0.735	0.391
Invasive ductal carcinoma	47 (78.33)	49 (84.48)
Other	13 (21.67)	9 (15.52)
KPNA2 expression			0.016	0.899
Positive	41 (68.33)	39 (67.24)
Negative	19 (31.67)	19 (32.76)
SOX2 expression			0.012	0.914
Positive	45 (75.00)	43 (74.14)
Negative	15 (25.00)	15 (25.86)
Ki-67			0.518	0.472
≤ 14%	17 (28.33)	20 (34.48)
> 14%	43 (71.67)	38 (65.52)
P53			0.210	0.647
Positive	39 (65.00)	40 (68.97)
Negative	21 (35.00)	18 (31.03)

KPNA2: Karyopherin A2; SOX2: SRY-related HMG box-2; BMI: Body mass index; TNM: Tumor-node-metastasis.